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Assessment of Myocardial Fibrosis
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Diffuse interstitial or replacement myocardial fibrosis is a common feature of a broad variety of cardiomyopathies.
Myocardial fibrosis leads to impaired cardiac diastolic and systolic function and is related to adverse cardiovascular
events. Cardiovascular magnetic resonance (CMR) may uniquely characterize the extent of replacement fibrosis and
may have prognostic value in various cardiomyopathies. Myocardial longitudinal relaxation time mapping is an
emerging technique that could improve CMR’s diagnostic accuracy, especially for interstitial diffuse myocardial fibro-
sis. As such, CMR could be integrated in the monitoring and therapeutic management of a large number of patients.
This review summarizes the advantages and limitations of CMR for the assessment of myocardial fibrosis. (J Am
Coll Cardiol 2011;57:891–903) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.013One of the most common histological features of the failing
heart is myocardial fibrosis. Replacement fibrosis, often
present in the terminal stages of heart failure, has been
reported in histopathological autopsy studies (1,2). The
pathophysiological mechanisms that lead to this fibrosis are
various, with some being acute, as in myocardial infarction
(3), and others being progressive and potentially reversible,
as in hypertensive cardiomyopathy (4). Myocardial fibrosis
in animal and patient studies is associated with worsening
ventricular systolic function, abnormal cardiac remodeling,
and increased ventricular stiffness (5–7). In recent clinical
studies, fibrosis has also been shown to be a major indepen-
dent predictive factor of adverse cardiac outcome (8–12).
In therapeutic guidelines for heart failure due to various
cardiomyopathies, there are no specific therapeutic strategies
based on the tissue composition of the myocardial wall, either
in the early or more advanced stages of disease. This lack of
specific treatment might result in inappropriate therapies,
which can lead to increased morbidity and additional financial
burden to health care services (13). Lack of personalized
treatment is also secondary to the absence of accurate clinical
tools to precisely phenotype patients with heart disease.
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2010, accepted November 19, 2010.Recent reports have demonstrated the advantages of
using cardiovascular magnetic resonance (CMR) for the
noninvasive imaging of heart failure patients (14,15). CMR
has been established as the reference imaging method for
the assessment of cardiac anatomy and function by provid-
ing highly accurate and reproducible measures of both the
left and right ventricles and also for the assessment of
myocardial viability (16–18). The field of CMR is rapidly
evolving with continuing technological progress and the
recent development of applications that have further en-
hanced its capacity to characterize myocardial tissue. In this
review, we focus on CMR characterization of the different
types of myocardial fibrosis and its etiology through late
gadolinium enhancement and myocardial longitudinal re-
laxation time (T1) mapping.
Myocardial Fibrosis:
Pathogenesis and Consequences
Fibrosis pathophysiology. In physiological conditions, the
fibrillar collagen network is in intimate contact with all the
different cell types of the myocardium and plays a critical
role in the maintenance of ventricular shape, size, and
function (Fig. 1).
Myocardial fibrosis, defined by a significant increase in
the collagen volume fraction of myocardial tissue, is always
present in end-stage heart failure (19). The distribution of
myocardial fibrosis, however, varies according to the under-
lying pathology and accounts for discrepancies among dif-
ferent pathological reports in which only qualitative as
opposed to quantitative measurements were made (19–22).
The progressive accumulation of collagen accounts for a
spectrum of ventricular dysfunctional processes that com-
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subsequently involve systolic
performance (5).
Subtypes of myocardial fibrosis.
Different types of myocardial fi-
brosis have been reported ac-
cording to the cardiomyopathic
process (Fig. 1).
REACTIVE INTERSTITIAL FIBROSIS.
The first type of fibrosis is inter-
stitial reactive fibrosis with a diffuse distribution within the
interstitium, but it can also be more specifically perivascular
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
LGE  late gadolinium
enhancement
LV  left ventricle
MOLLI  Modified Look-
Locker Inversion Recovery
Figure 1 Etiophysiopathology of Myocardial Fibrosis
Myocardial fibrosis is a complex process that involves each cellular component of
by increasing the production of collagen and other extracellular matrix components
pro-inflammatory cytokines, reactive oxygen species).(23). This type of fibrosis has a progressive onset and
follows the increase in collagen synthesis by myofibroblasts
under the influence of different stimuli. It has mostly been
described in hypertension and diabetes mellitus, where the
activation of the renin-angiotensin aldosterone system,
beta-adrenergic system, the excess of reactive oxygen spe-
cies, and metabolic disturbances induced by hyperglycemia
are major contributors (23–28) (Fig. 2). But this type of
fibrosis is also present in the aging heart, in idiopathic
dilated cardiomyopathy (2,21), and in left ventricular (LV)
pressure-overload and volume-overload states induced by
chronic aortic valve regurgitation and stenosis (29,30). It has
yocardial tissue. The myocardial fibroblast has a central position in this process
r the influence of various factors (renin-angiotensin system, myocyte apoptosis,the m
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s
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after infarction (31).
Interstitial fibrosis is an intermediate marker of disease
severity, as has been shown in hypertensive cardiomyopathy,
and it precedes irreversible replacement fibrosis (27,32). It is
reversible under specific therapy (4,33,34). Therefore, there
is some clinical interest in its assessment for the manage-
ment of patients with hypertension, diabetes, primary di-
lated cardiomyopathy, and valvular disease.
INFILTRATIVE INTERSTITIAL FIBROSIS. This subtype of fi-
brosis is induced by the progressive deposit of insoluble
proteins (amyloidosis) or glycosphingolipids (Anderson-
Fabry disease) (35,36) in the cardiac interstitium. Although
this subject is not the primary focus of this review, their
pathophysiology follows similar patterns, and the early
detection of cardiac involvement is of critical importance to
therapeutic management.
REPLACEMENT FIBROSIS. This replacement or scarring fibro-
sis corresponds to the replacement of myocytes after cell
damage or necrosis by plexiform fibrosis, mainly type I collagen
(37). Replacement fibrosis appears as soon as the myocyte
integrity is affected. It can have a localized distribution (isch-
emic cardiomyopathy, myocarditis, hypertrophic cardiomyop-
athy, sarcoidosis) or a diffuse distribution (chronic renal insuf-
ficiency, toxic cardiomyopathies, miscellaneous inflammatory
disease) according to the underlying etiology (14,15,38).
Interstitial fibrosis and infiltrative fibrosis ultimately lead
to replacement fibrosis in the later stages of disease, where
cellular damage and cardiomyocyte necrosis/apoptosis
appear (27).
Detection of Myocardial Fibrosis
Endomyocardial Biopsies
Previously, the only methodology available to assess myo-
Figure 2 Diabetic Cardiomyopathy
Mild myocardial interstitial fibrosis stained in blue with Masson trichrome (white a
with (A) perivascular fibrosis and (B) mild fibrosis between myocytes. Reprinted wcardial fibrosis was the histopathological assessment of aendomyocardial tissue biopsies or of autopsy pieces. This
methodology enables qualitative macroscopic assessment
after Masson Trichrome staining (22) and quantitative
absolute assessment of the collagen volume fraction in tissue
samples by quantitative morphometry with picrosirius red,
which specifically stains fibrillar collagen under polarized
light (1,21,39). Although this technique offers an absolute
quantification of fibrosis in myocardial samples (3), it has 3
evident drawbacks: 1) invasive biopsies are required;
2) sampling error restricts the accuracy of biopsy in the case
of localized fibrosis (7,40); and 3) fibrotic involvement of
the whole LV cannot be determined.
CMR
In the last 10 years, CMR has emerged as a noninvasive
imaging method that allows a comprehensive assessment of
myocardial anatomy and function with unequaled levels of
accuracy and reproducibility. The use of gadolinium extracel-
lular contrast agents with CMR using late post-gadolinium
myocardial enhancement (LGE) sequences have further
pushed our ability to accurately and precisely analyze myocar-
dial tissue composition, especially myocardial fibrosis content.
Physical basis of CMR tissue characterization. T1, T2
RELAXATION TIMES, PROTON DENSITY. In CMR images,
the pixel signal intensity is based on the relaxation of
hydrogen nuclei protons in the static magnetic field, of
typically 1.5- or 3.0-T scanners. The relaxation of the
hydrogen nucleus proton is specifically characterized by 2
distinct magnetic resonance relaxation parameters: 1) the T1
or spin-lattice relaxation time, which corresponds to the
specific time decay constant when the proton recovers
approximately 63% of its longitudinal magnetization equi-
librium value; and 2) the transverse relaxation time (T2) or
pin-spin relaxation time, which corresponds to the specific
ime when the proton transverse magnetization drops to
) in a patient with long-duration type 1 diabetes mellitus at autopsy,
mission from Konduracka et al. (28).rrows
ith perpproximately 37% of its original value. Both of those times
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rameter that needs to be added to explain the pixel signal
intensity is the density of mobile hydrogen atoms within the
tissue voxel or proton density.
Both the T1 and T2 relaxation times depend on the
olecular environment of the water molecules in the tissue
nd therefore characterize each tissue very specifically. T1
and T2 relaxation times vary significantly from one type of
issue to another, but also within the same tissue depending
n its physiopathological status (inflammation, edema, fi-
rosis). The CMR imaging techniques used also result in
ifferent contrast images. Specific CMR sequences can be
sed to selectively reveal certain molecular environments
ithin the tissue. Those differences are further enhanced
ith the use of gadolinium extracellular magnetic resonance
ontrast agents.
GADOLINIUM CMR ENHANCEMENT. Gadolinium contrast
gents reduce the T1 relaxation time of adjacent tissue.
Thus, the local gadolinium tissue concentration will induce
differences in signal intensity in the T1-weighted image.
Given various specific properties of the tissue, the T1
shortening induced by the gadolinium contrast agent gen-
erates specific differences in signal intensity. The major
tissue parameters that influence the final voxel signal inten-
sity in the contrast-enhanced images are local perfusion;
extracellular volume of distribution; water exchange rates
among the vascular; interstitial, and cellular spaces; and
wash-in and wash-out kinetics of the contrast agent (41,42).
GADOLINIUM CMR OF MYOCARDIAL FIBROSIS ENHANCED.
The physiological basis of the LGE of myocardial fibrosis is
based on the combination of an increased volume of
Different Prevalence Reports of Myocardial Scarring/Fibrosis of theas Defined With Qualitative Analysis of LGE Card ovascular MagnetTable 1 Diff rent Pre alence Rep ts of Myocardial Scarrin /Fas Defined With Qualitative Analysis of LGE Cardiovasc
Cardiac Disease Category (Ref. #)
Total
Patients (n)
Prevalence of
Fibrosis (%) Pre
NIDCM (8,40,50–55) 350 47
HCM (51,56–68) 1,654 69
Aortic valve disease (65,69,70) 153 46
Pulmonary sarcoidosis (71–73) 170 28
Cardiac amyloidosis (74,75) 54 72.5
Hypertensive cardiomyopathy (65,76) 1,670 39
Diabetic cardiomyopathy (12) 107 28
Heart transplant (77) 53 51
Thalassemia major (78) 115 24
Chagas disease (79) 51 69
Chronic hemodialysis (80) 24 79HCM  hypertrophic cardiomyopathy; LGE  late gadolinium enhancement; LV  left ventricle; NA  nodistribution for the contrast agent and a prolonged wash-out
related to the decreased capillary density within the myo-
cardial fibrotic tissue (41,43). The increase in gadolinium
concentration within fibrotic tissue causes T1 shortening,
hich appears as bright signal intensity in the CMR image
ased on conventional inversion-recovery gradient echo
equences. Thus, the discrimination between scarred/
brotic myocardium and normal myocardium relies on
ontrast concentration differences combined with the cho-
en setting of the inversion-recovery sequence parameters.
hese parameters are set to “null” the normal myocardial
ignal that appears dark in the final image relative to the
right signal of the scarred/fibrotic myocardium.
Of note, gadolinium contrast agents are not specific
arkers for myocardial fibrosis. Late gadolinium enhance-
ent is caused by modifications of the contrast distribution
pace as well as wash-in and wash-out kinetics of the contrast
nto interstitial space or extracellular matrix. Therefore, quan-
ification of late enhancement (e.g., T1 mapping) explores the
volume of the extracellular matrix. This volume is increased in
myocardial fibrosis but can also be increased in other patho-
logical processes, such as inflammation and edema.
Measuring myocardial fibrosis with LGE. CLINICAL
APPLICATIONS. The clinical application of myocardial
GE with CMR started with the assessment of experimen-
al acute myocardial infarction followed by measurements in
hronic infarct experimental models and patients (44–46).
fter having shown that the regional differences in signal
ntensity were correlated to the extent and severity of
yocardial injury, Kim et al. (47) reported in experimental
tudies that the spatial extent of hyperenhancement was the
ame as the spatial extent of the collagenous scar at 8 weeks
in Various Nonischemic Cardiac Pathologiessonancei of the LV i Various Nonischemic Card ac Pathologies
Magnetic Resonance
of
e (%) LGE Pattern LGE Preferential Location
Mid-wall, patchy foci, subendocardial
nonsystemized
Septum, RV-LV insertion
points
0 Mid-wall, diffuse, heterogeneous Within hypertrophied regions,
RV-LV insertion points
Mid-wall, multifocal Very variable, basal septum
and inferior walls
Mid-wall, subepicardial, ischemic-like Inferoseptal-, inferolateral-
basal
Diffuse subendocardial, patchy
subendocardial
Global
Patchy, nonspecific, ischemic
pattern
None
Nonspecific, ischemic pattern None
Ischemic pattern, midwall,
diffuse, spotted
Inferoseptal
Multifocal, epicardial, midwall Inferoseptal, septum
Subendocardial ischemic-like,
subepicardial
Inferolateral, global
Ischemic pattern, diffuse,
midwall-focal
NoneLVic Reibros
ular
Range
valenc
9–88
45–10
27–62
26–32
69–76
28–50
NA
NA
NA
NA
NAt applicable; NIDCM  nonischemic dilated cardiomyopathy; RV  right ventricle.
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LGE extent in patients with chronic ischemic cardiomyop-
athy was further demonstrated with the clinical study in 50
patients undergoing revascularization showing that the de-
gree of improvement in the global mean wall-motion score
and the ejection fraction was significantly related to the
transmural extent of LGE (46).
During the chronic phase of infarction, when a dense
fibrotic scar replaces the infarcted myocardium, Mahrholdt
et al. (17) showed the accuracy and the clinical reproduc-
ibility of delayed enhancement for infarct size determina-
tion. Moreover, Ricciardi et al. (48) and Wu et al. (49)
showed the higher sensitivity for infarct detection by LGE-
CMR as compared with single-photon emission computed
tomography, and other studies have confirmed the ability of
CMR to detect microinfarctions.
The number of studies assessing myocardial fibrosis by
LGE in other types of cardiomyopathies has dramatically
increased in the last 10 years (Table 1) (12,40,50–80).
Different patterns of enhancement have been reported
according to the underlying etiology, and LGE-CMR has
become a first-line noninvasive exam for the etiologic
assessment of new-onset myocardial dysfunction (14,15,50).
LGE-CMR also provides prognostic information that
could be used to define more appropriate therapeutic strat-
egies. In ischemic cardiomyopathy, the transmural extent of
LGE is predictive of myocardial wall recovery after revas-
cularization, but it is also predictive of adverse LV remod-
eling (46,81). At the clinical level, infarct size is an inde-
pendent prognostic factor for heart failure, arrhythmic
events, and cardiac mortality (9,11,82). In nonischemic
dilated cardiomyopathy, Assomull et al. (8) showed that the
presence of myocardial LGE was associated with a 3-fold
increase of hospitalization for heart failure or cardiac death
and a 5-fold increase of sudden cardiac death or ventricular
arrhythmias. In hypertrophic cardiomyopathy, Rubinshtein
et al. (56) and Kwon et al. (57) reported that LGE was
strongly associated with arrhythmia and remained signifi-
cantly associated with subsequent sudden cardiac death after
adjustment for other risk factors. In the same way, LGE is
significantly and independently associated with adverse
cardiac events in patients with cardiac amyloidosis (74) and
in patients undergoing aortic valve replacement (83). Re-
cently, the additional prognostic value of LGE was dem-
onstrated in hypertensive (76) and diabetic (12) patients free
of any cardiac symptoms and with preserved ejection frac-
tion. Finally, the clinical significance of LGE also offers
potential targets for new therapeutic strategies designed for
the purpose of personalizing medical management, al-
though such paradigm requires further development and
testing. In this regard, there is a crucial need for LGE-
CMR assessment standardization in clinical practice (84).
LGE LIMITATIONS. If LGE allows a sensitive and reproduc-
ble qualitative assessment of myocardial replacement fibro-
is, it is limited in its accuracy for absolute quantification of iyocardial fibrosis, and the assessment of diffuse fibrosis is
estricted by technical and physiopathological characteris-
ics. First, with conventional LGE imaging sequences,
ignal intensity is expressed on an arbitrary scale that differs
rom one imaging study to another and therefore is unsuit-
ble for direct signal quantification in cross-sectional or
ongitudinal comparisons. The late gadolinium-enhanced
yocardial fibrotic tissue is defined on the basis of the
ifference in signal intensity between fibrotic and normal
yocardium, and this difference generates the image con-
rast. In addition, LGE is influenced not only by tech-
ical parameters set during image acquisition (inversion
ime [85], slice thickness, and so on), but also according
o the intensity threshold that is arbitrarily set during
ost-processing to differentiate normal from fibrotic
yocardium (86).
Presently, there is no clear consensus on the intensity
hreshold settings to use for clinical assessment of myocar-
ial fibrosis. Various methods have been reported to define
ate enhanced myocardium, with significantly different re-
ults (86–89). This is one of the factors explaining the
ariability in the frequency of myocardial fibrosis found by
GE in various cardiomyopathies from different studies
Table 1). This questions the reliability and reproducibility
f LGE for myocardial fibrosis quantification in a clinical
etting.
Another concern with the use of myocardial LGE has
merged with its increasing use to define the myocardial
gray zone” in clinical studies. The “gray zone” has been
rbitrarily defined on late enhancement CMR images as
yocardium with intermediate signal intensity enhancement
etween normal and scarred/fibrotic myocardium (90). This
rea reflects tissue heterogeneity within the infarct periphery
nd has been shown to strongly correlate with ventricular
rrhythmia inducibility and post-myocardial infarction mortal-
ty in ischemic cardiomyopathy (90,91). The use of this “gray
one” in ischemic cardiomyopathy and other types of cardio-
yopathies further expands the assessment and the quantifi-
ation of hyperenhanced myocardium for purposes that go
eyond pure quantification of myocardial fibrosis.
Finally, although LGE-CMR is the most accurate
ethod to measure myocardial replacement fibrosis, its
ensitivity is limited for the assessment of diffuse interstitial
brosis. In LGE-CMR, image contrast relies on the differ-
nce in signal intensity between fibrotic and “normal”
yocardium, and such differences may not exist if the
rocess is diffuse.
easuring myocardial fibrosis with T1 mapping.
T1 MAPPING BASICS. The recent technical improvements in
acquisition sequences now enable us to perform myocardial
T1 mapping with high spatial resolution by using 1.5-T
magnetic resonance imaging scanners within a single breath
hold (92). Compared with LGE images, T1-mapping CMR
echniques allow us to eliminate the influences of window-
ng and variations in signal enhancement by directly mea-
896 Mewton et al. JACC Vol. 57, No. 8, 2011
Cardiovascular Magnetic Resonance and Fibrosis February 22, 2011:891–903Figure 3 T1 Map Construction and T1 Recovery Graph After Contrast Administration
(A) T1 map after 15 min of gadolinium administration in an inferior infarct case. This is the Modified Look-Locker Inversion Recovery Sequence that uses 17 heart-beats
to reconstruct 11 images with different inversion times during mid-diastole. It is necessary to combine all images to generate the final T1 map. For that, it is necessary
to apply algorithms to define the best fitting curve over the 11 acquired initial voxels linking for the same location. Those fitting algorithm are very sensitive to motion
and image quality/artifacts. The result is a T1 map imaging where the T1 time for the global or segmented left ventricle can be assessed. (B) Graph showing the recov-
ery of absolute myocardial T1 value in a healthy heart (short axis, mid-ventricle) at different time points before and after contrast administration (0, 2, 4, 6, 8, 10, 15,
and 20 min). T1 values are expressed as mean  SD. The global and regional mean T1 values will vary significantly with the time of assessment. The SD of T1 value is
more significant before contrast administration. Reprinted with permission from Messroghli et al. (93).
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allows signal quantification (in milliseconds) on a standard-
ized scale of each myocardial voxel to characterize myocar-
dial tissue.
T1 MAPPING METHODOLOGY. A T1 map of the myocar-
dium is a parametric reconstructed image, where each pixel’s
intensity directly corresponds to the T1 relaxation time of
he corresponding myocardial voxel. Signal recovery from
ach myocardial voxel is sampled with multiple measure-
ents after a specific preparation pulse sequence, and the
ssociated T1 relaxation time is calculated from these
easurements by the combination of all acquisitions. T1
maps can be obtained any time before or after gadolinium
contrast administration. The pre-contrast T1 map is a
aseline reference. The post-contrast T1 maps are assessed
at different time points after contrast administration and
could be used to obtain the curve of myocardial T1 recovery
reflecting the contrast agent wash-out (Fig. 3) (93).
Different CMR acquisition sequences have been used to
obtain myocardial T1 maps (6,75,92,94,95). This is an
essential point to consider before performing myocardial T1
maps, because it directly influences the accuracy and repro-
ducibility of the final T1 measurements. This should also be
onsidered when comparing results between different stud-
es. Different T1 mapping strategies will have varying
ensitivities to motion artifacts, heart rate, and intrinsic T1
value ranges (94).
The most assessed T1 mapping sequence has been de-
cribed by Messroghli et al. (92,94,96,97) and is the
odified Look-Locker Inversion-recovery (MOLLI) se-
uence. MOLLI provides high-resolution T1 maps of
human myocardium in native and post-contrast situations
within a single breath hold.
This sequence has been thoroughly described, optimized,
and tested in phantom studies, on healthy volunteers, and
ischemic cardiomyopathy patients. Although it is sensitive to
Figure 4 T1 Maps of the Myocardium at the Mid-Ventricular Sh
(A) Pre-contrast, (B) post-gadolinium contrast (0.15 mmol/kg) at 12 min, and (C)
The mean T value for the left ventricle (LV) can be obtained at each time after tra1heart rate extreme values and tends to slightly underestimate
the true heart T1 value, the method allows a rapid and highly
eproducible T1 map of the heart with high levels of intra and
nter-observer agreement (93). However, in the only report on
he clinical validation of T1 mapping against histology for the
ssessment of myocardial fibrosis, Iles et al. (6) used a different
ype of sequence (VAST [Variable Sampling of the k-space in
ime] inversion-recovery prepared 2D fast gradient echo
equence with variable sampling of k-space). This sequence,
hich is very similar to the MOLLI sequence, has been less
ell validated in the literature.
T1 maps can be obtained at different slice levels, with an
verage acquisition time of 15 to 20 s (1 breath hold) for 1
1 map (93). Figure 4 demonstrates T1 maps at the
mid-ventricle level.
THE ADVANTAGES OF T1 MAPPING. T1 mapping enables
direct myocardial signal quantification (in milliseconds) on a
standardized scale. This allows a better characterization of
myocardial tissue composition on a global or regional level.
Myocardial areas of delayed enhancement can be measured
in terms of their spatial extent, but also in terms of the
magnitude of their signal intensity: The composition of
each myocardial slice can be analyzed as a T1 distribution
histogram, which gives a more accurate description of the
myocardial tissue composition (Fig. 5). One hypothesis
would be to use this T1 distribution (mean T1 peak value,
distribution scatter) to identify specific myocardial patterns
such as myocardial diffuse fibrosis, specific myopathies, or
the peri-infarction or “gray zone.”
The pre-contrast mean T1 value of normal myocardium is
f 977  63 ms, and the post-contrast values between 10
nd 15 min of normal myocardium have been reported to be
pproximately 483  20 ms (93) at 1.5-T. Pre-contrast T1
values of myocardial fibrosis (infarct scar) are significantly
longer than those of normal myocardium (1,060 61 ms vs.
xis Level in a Healthy Volunteer
min acquired with the MOLLI sequence.
he endocardial and epicardial countours of the LV (A).ort-A
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distribution overlaps with that of fibrotic myocardium (97).
Post-contrast T1 values of scarred myocardium (replace-
ment fibrosis) are significantly shorter than those of normal
myocardium due to the retention of gadolinium contrast in
fibrotic tissue. Messroghli et al. (97) reported T1 values of
approximately 390  20 ms in chronic infarct scar com-
pared with 483 23 ms in normal myocardium for T1 maps
obtained between 10 and 15 min after contrast administra-
tion at 0.15 mmol/kg.
The accuracy of post-contrast T1 mapping to assess
yocardial interstitial and replacement fibrosis has had
imited validation. In a study of 9 patients after cardiac
ransplantation, T1 time at 15 min after gadolinium admin-
stration showed an inverse correlation with myocardial
ollagen content.
Even if there is overlap between T1 values for interstitial
and replacement fibrosis, T1 mapping can accurately differ-
ntiate both interstitial and replacement fibrosis from nor-
al myocardium (98). In an in vitro magnetic resonance
Figure 5 Comparison of Late Gadolinium Enhanced Studies Wit
T1 Maps and T1 Values Distribution Histograms in Diff
(A) Chronic inferior myocardial infarction; (B) cardiac amyloidosis; (C) nonischemi
images with different patterns of enhancement, transmural localized in the case o
loidosis (B1), or sub-epicardial and heterogeneous in the case of dilated cardiomy
obtained after MOLLI acquisitions. From those T1 maps, a mean left-ventricular (L
through the analysis of the distribution histogram of the LV T1 values. Very distinc
further larger clinical studies. This might also be a new way to assess and quantiftudy of selected human myocardium samples, Kehr et al.98) showed that post-contrast T1 values for both diffuse
and replacement fibrosis were significantly different from T1
values for normal myocardium. Although there was no
significant difference between the respective diffuse fibrosis
and replacement fibrosis T1 values, there was a significant
correlation between T1 value and myocardial collagen con-
tent. However, the real clinical benefit of T1 mapping
emains to be shown. When applied with rigorous method-
logy, T1 mapping could be the ideal tool to assess and
uantify diffuse myocardial fibrosis. It could also improve
he accuracy of delayed enhancement and myocardial scar
haracterization.
REPORTED CLINICAL APPLICATIONS OF T1 MAPPING.
There are very few studies published using T1 mapping in the
linical setting. They are reported in Table 2 (6,75,96,98,99).
T1 MAPPING LIMITATIONS. To date, all of the published
linical studies using T1 mapping have been realized on
small groups of selected patients, with different types of T1
acquisition sequences. Although the use of T1 mapping for
rresponding
Cardiomyopathies
ed cardiomyopathy. In each example, the short-axis late gadolinium images show
ocardial infarction scar (A1), sub-endocardial diffuse in the case of cardiac amy-
y (C1). In the middle panel are the corresponding T1 maps (A2, B2, B3)
alue can be obtained. This information can also be processed more precisely
rns of distributions can be seen on those examples, but this has to be shown in
ardial fibrosis.h Co
erent
c dilat
f a my
opath
V) T1 v
t patte
y myocmyocardial fibrosis assessment appears to be promising
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to many confounding factors. Those factors are as follows:
1. The physical properties of gadolinium contrast agents
(dose, concentration, relaxivity, rate of injection, and
water exchange rate) significantly affect the final myo-
cardial voxel T1 value.
. The time delay of the T1 mapping measurement after
gadolinium administration also significantly affects the
resulting T1 values. Because the T1 value exponentially
increases with the wash-out of gadolinium contrast from
the myocardium, the time of T1 mapping acquisition will
have a significant influence on the final myocardial voxel
T1 value (93). Therefore, in clinical studies, when per-
forming T1 mapping acquisition, the acquisition time
after contrast administration should be carefully moni-
tored and reported. Solutions to this problem may
include normalization to noncardiac tissue (e.g., muscle,
blood) or characterization of the time as a T1 curve.
. The types of T1 mapping acquisition sequence that will
affect the sensitivity to motion artifacts (arrhythmia),
Clinical Studies Using T1 MappingTable 2 Clinical Studies Using T1 Mapping
First Author (Ref. #) Cardiac Disease Category
Patient Sampl
(n)
Messroghli et al. (96) Acute myocardial infarction 8
Messroghli et al. (98) Chronic myocardial infarction 24
Sparrow et al. (99) Chronic aortic regurgitation 8
Maceira et al. (75) Cardiac amyloidosis 22
Iles et al. (6) Chronic heart failure 25
LGE  late gadolinium enhancement; MOLLI  Modified Look-Locker Inversion Recovery; NA  n
in Time.heart rate, and T1 extreme values (92,94). Recently,various acquisition protocols with shorter acquisition
times have been reported with good levels of accuracy
(100,101).
. The gadolinium myocardial wash-out rate, which mainly
depends on each patient’s individual glomerular filtration
rate, should be carefully accounted for when performing
T1 mapping. Although the influence of renal dysfunction
on myocardial T1 mapping remains incompletely under-
stood, Maceira et al. (75) proposed a correction model of
myocardial T1 value by blood T1 value in their study of
cardiac amyloid patients that significantly improved T1
mapping sensitivity.
. The presence of LGE areas will have to be accounted for
in order to assess the true T1 value of nonaffected
myocardial areas. Those areas have been shown to
significantly influence global myocardial slice mean T1
value and therefore interfere with the diagnosis of diffuse
interstitial fibrosis (6).
. The hematocrit level will affect the partition coefficient
of the gadolinium contrast agent to be considered for the
T1 Mapping Method Results
NA ● T1 pre-contrast value of the infarcted
myocardium was significantly prolonged
(18 7%) compared with noninfarcted
normal myocardium.
● T1 10-min post-contrast value of the
infarct was significantly reduced
(–27 4%) compared with normal
myocardium.
MOLLI ● T1 pre-contrast value of the infarcted
myocardium was significantly prolonged
compared with noninfarcted normal
myocardium (1,060 61 ms vs.
987 34 ms).
● T1 post-contrast value of the infarct was
significantly reduced compared with
normal myocardium.
● Difference between baseline and post-
contrast T1s significantly more pronounced
in the acute than in the chronic studies at
all time points.
MOLLI ● No significant difference in slice averaged
myocardial T1 pre- and post-contrast
values in the patient group compared with
controls.
NA ● Subendocardial T1 post-contrast value at 4
min was significantly shorter in amyloid
patients than in controls (427 73 ms vs.
579 75 ms).
VAST ● T1 15-min post-contrast values correlated
significantly with collagen volume fraction
on myocardial biopsies (R  –0.7).
● T1 15-min post-contrast values were
significantly shorter in heart failure
patients than controls (383 17 ms vs.
564 23 ms) even after exclusion of LGE
areas.
icable; VAST  inversion recovery gradient echo sequence with Variable Sampling of the k-spacee Sizeclinical use of T1 mapping.
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same between basal, mid-cavity, and apical sections of
the LV in healthy volunteers, it is unknown whether all
sections are affected equally by diffuse interstitial fibrosis.
For practical reasons, T1 maps in patients are performed
at a single-section level of the LV (usually mid-
ventricle). Therefore, this sampling limitation might
affect the final T1 values in a myocardium in which the
fibrosis process is not homogenous.
T1 mapping is a very sensitive technique that needs to be
erformed in rigorous conditions in order to enhance its
ccuracy for fibrosis assessment and allow cross-sectional
omparisons (102). Although the post-contrast T1 value of
yocardial fibrosis is significantly different from that of
ormal myocardium, myocardial T1 distribution can be
ignificantly scattered, and this might limit its sensitivity for
isease states with less severe fibrosis.
T1 mapping is still an emerging technique. Before it can
be used for clinical applications, a more standardized histo-
logically validated technique needs to be identified and
assessed in clinical studies on various and larger groups of
patients and in multicenter settings.
Equilibrium contrast CMR. Recently Flett et al. (103)
reported a new CMR method to assess diffuse myocardial
fibrosis: equilibrium contrast CMR. This was implemented
to improve myocardial T1 mapping by excluding confound-
ng factors such as heart rate, body composition, and renal
learance variability. It is based on 3 elements: 1) a bolus of
adolinium followed by continuous infusion to achieve
lood/myocardium equilibrium; 2) a measurement of the
lood volume of distribution (1-hematocrit); and 3) a pre-
nd post-equilibrium T1 measurement by CMR. This
ethod allows a precise calculation of the gadolinium
yocardial volume distribution that reflects diffuse myocar-
ial fibrosis.
In a selected population of pre-surgical aortic stenosis and
ypertrophic cardiomyopathy patients undergoing myec-
omy, Flett et al. (103) validated this method against fibrosis
uantification by histology on selective surgical biopsies.
hey showed that equilibrium contrast CMR correlated
trongly with biopsy histological fibrosis. These data are
reliminary and, as for T1 mapping, have to be confirmed in
larger and different cardiomyopathy populations. Also, this
method imposes a more complex image acquisition protocol
that questions its clinical applicability at the time when
CMR availability is still a major limitation in comparison
with other cardiac imaging techniques.
Other Methods to Explore Myocardial Fibrosis
This review focuses on CMR as the most promising
accessible and accurate noninvasive imaging tool to assess
myocardial fibrosis in a routine clinical practice. Other
noninvasive methods have been used to characterize myo-
cardial fibrosis (perfusable tissue index with positron emis-
sion tomography, procollagen-derived pro-peptides andmatrix metalloproteinases as serum fibrosis biomarkers,
single-photon emission computed tomography imaging
with specific radiolabeled agents) or its functional conse-
quences (tissue Doppler echocardiography, CMR tissue
tagging) and have been reported in the literature (104) but
do not constitute the focus of this review. The cross-
sectional combination of different imaging modalities might
increase the diagnostic accuracy for myocardial fibrosis, but
this still needs to be established.
Future Perspective
CMR has recently been proposed as a comprehensive tool in
the clinical arena for the diagnosis and management of
patients with heart failure (14). LGE-CMR, after showing
its prognostic power to predict myocardial recovery in
ischemic cardiomyopathy, has also shown its diagnostic
accuracy for myocardial replacement fibrosis assessment in
different types of cardiomyopathies. LGE presence has a
powerful independent clinical prognostic value not only in
ischemic cardiomyopathy (9,11,81,82), but also in all other
types of cardiomyopathies (8,69,74,105). This knowledge is
now being converted in efficient methods to monitor ther-
apeutic applications through new studies designed to im-
prove our therapeutic options.
The emergence of T1 mapping further improves our
nowledge and the clinical assessment of myocardial diffuse
brosis and further refines the information provided by
GE-CMR. It might help us to better stratify much larger
nd lower cardiovascular risk patient populations (diabetics,
ypertensive), detecting subclinical myocardial changes be-
ore the onset of diastolic and systolic dysfunction. For the
oment, clinical data are scarce, and the clinical value of
his technique remains to be shown, specifically in larger
roups of patients and in prospective studies. T1 mapping
sing standardized imaging protocols combined with LGE
ill be of great help for a more precise myocardial tissue
haracterization. This combination of tissular information
ight help the clinician to better understand and diagnose
ooner the underlying cardiomyopathic process. This infor-
ation will also help to improve therapeutic strategies and
nable a more direct monitoring of their effect, thus im-
roving clinical outcomes (4,32).
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